evidence of metastatic disease;

inflammatory breast cancer;

prior hormonal or systemic therapy for breast cancer;

prior treatment with an agent targetting the IGF-1R pathway;

patients receiving concurrent radiotherapy, or who have received radiotherapy within 28 days prior to receipt of study drug.

A Study to Evaluate the Biological Activity of R1507 in Women With Operable Breast Cancer